Project Details
Description
OVERALL SUMMARY
The Dana Farber/Harvard Cancer Center (DF/HCC) multiple myeloma (MM) SPORE renewal application
consists of 3 Research Projects and 3 Cores, as well as the Career Enhancement and Developmental Research
Programs. During the previous funding period, we have capitalized on the complementary strengths of the
research, clinical expertise, and facilities of the Harvard affiliated institutions including Dana Farber Cancer
Institute, Massachusetts General Hospital, Harvard Medical School, and Harvard School of Public Health. We
have successfully translated multiple novel agents from the bench to the bedside and FDA approval for treatment
of MM. In this SPORE renewal application one new project has evolved from prior Developmental Projects, and
three investigators who are now Co-PI's have previously received Developmental Research or Career
Enhancement Awards. This new project focuses on developing novel therapeutic strategies in Waldenstrom's
macroglobulinemia, a plasma cell disorder with unique biology. The group as a whole has a long-term
commitment to translational MM research, with the necessary administrative, basic science, and clinical
infrastructure. At our well established centers, more than 750 new patients with MM are evaluated annually, as
well as 10,000 outpatient visits for established patients with plasma cell dyscrasias. The spectrum of diseases
evaluated spans from monoclonal gammopathy of unclear significance to plasma cell leukemia to Waldenstrom's
macroglobulinemia. Our center has appropriate scientific and institutional review boards, as well as protocol
audit and quality control centers, to conduct cutting-edge translational research. This large combined patient
base assures rapid accrual and evaluation of the therapeutic efficacy of novel agents identified in this program
with over 40 active protocols. Success of both the preclinical and clinical components of this Program is
dependent upon synergy and communication between these investigators which is assured by the access to all
the Principal Investigators to the preclinical data generated in joint research efforts. Currently there is systematic
quality-controlled exchange of bone marrow and blood samples for correlative basic laboratory studies. The
overall goal of this DF/HCC myeloma SPORE is to take advantage of our increased understanding of the genetic
and molecular basis of multiple myeloma and Waldenstrom's macroglobulinemia to develop novel, effective
therapeutic strategies for patients. The translational nature of the SPORE is highlighted by the fact that most of
our projects have emanated from clinical studies from the outset. Specific Projects are: (1) Therapeutically
Targeting Ubiquitin Receptors in Multiple Myeloma; (2) Targeting AP Nuclease, a Mediator of Genomic Instability
in MM; (3) Targeting Mutated MYD88 Signaling in WM; An Administration Communication and Planning Core;
as well as Tissue Core 1 and Biostatistics and Bioinformatics Core 2, will continue to support the program. This
Program therefore helps move rational novel targeted therapies from the laboratory to clinical protocols to
improve patient outcome in MM.
Status | Active |
---|---|
Effective start/end date | 9/16/03 → 5/31/24 |
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.